Citations

Showing 10 of 107854 citations.

Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, Johannes D. , Roemmich, James N. , Richmond, Erick , Rogol, Alan D. , Lovejoy, Jennifer C., Sheffield‐Moore, Melinda , Mauras, Nelly , Bowers, Cyril Y.

Mayo Clinic

Endocrine Reviews | February 2, 2005 | Volume: 26 | Issue: 1 | Pages: 114-146

10.1210/er.2003-0038 | PMID 15689575 Get It

Cellular Stress Failure in Ventilator-injured Lungs
Vlahakis, Nicholas E., Hubmayr, Rolf D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 2, 2005 | Volume: 171 | Issue: 12 | Pages: 1328-1342

10.1164/rccm.200408-1036so | PMID 15695492 Get It

Abstract The clinical and experimental literature has unequivocally established that mechanical ventilation with large tidal volumes is injurious to the lung. However, uncertainty about the micromechanics of injured lungs and the numerous degrees of freedom in ventilator settings leave many unanswered questions about the biophysical determinants of lung injury. In this review we focus on experimental evidence for lung cells as injury targets and the relevance of these studies for human ventilator-associated lung injury. In vitro, the stress-induced mechanical interactions between matrix and adherent cells are important for cellular remodeling as a means for preventing compromise of cell structure and ultimately cell injury or death. In vivo, these same principles apply. Large tidal volume mechanical ventilation results in physical breaks in alveolar epithelial and endothelial plasma membrane integrity and subsequent triggering of proinflammatory signaling cascades resulting in the cytokine milieu and pathologic and physiologic findings of ventilator-associated lung injury. Importantly, though, alveolar cells possess cellular repair and remodeling mechanisms that in addition to protecting the stressed cell provide potential molecular targets for the prevention and treatment of ventilator-associated lung injury in the future.
Hypercapnic Acidosis Impairs Plasma Membrane Wound Resealing in Ventilator-injured Lungs
Doerr, Clinton H., Gajić, Ognjen, Berríos, Jorge, Caples, Sean M., Abdel, Matthew, Lymp, James, Hubmayr, Rolf D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 2, 2005 | Volume: 171 | Issue: 12 | Pages: 1371-1377

10.1164/rccm.200309-1223oc | PMID 15695495 Get It

Abstract The objective of this study was to assess the effects of hypercapnic acidosis on lung cell injury and repair by confocal microscopy in a model of ventilator-induced lung injury. Three groups of normocapnic, hypocapnic, and hypercapnic rat lungs were perfused ex vivo, either during or after injurious ventilation, with a solution containing the membrane-impermeant label propidium iodide. In lungs labeled during injurious ventilation, propidium iodide fluorescence identifies all cells with plasma membrane wounds, both permanent and transient, whereas in lungs labeled after injurious ventilation propidium iodide fluorescence identifies only cells with permanent plasma membrane wounds. Hypercapnia minimized the adverse effects of high-volume ventilation on vascular barrier function, whereas hypocapnia had the opposite effect. Despite CO2-dependent differences in lung mechanics and edema the number of injured subpleural cells per alveolus was similar in the three groups (0.48 ± 0.34 versus 0.51 ± 0.19 versus 0.43 ± 0.20 for hypocapnia, normocapnia, and hypercapnia, respectively). However, compared with normocapnia the probability of wound repair was significantly reduced in hypercapnic lungs (63 versus 38%; p < 0.02). This finding was subsequently confirmed in alveolar epithelial cell scratch models. The potential relevance of these observations for lung inflammation and remodeling after mechanical injury is discussed.
Integrative Tumor Board: Medical and Surgical Oncology Approach
Hogan, Thomas F., Lamm, Donald L.

Mayo Clinic

Integrative Cancer Therapies | February 2, 2005 | Volume: 4 | Issue: 1 | Pages: 50-52

10.1177/1534735404274349 Get It

Nephron Distribution of Total Low Km Cyclic AMP Phosphodiesterase in Mouse, Rat and Rabbit Kidney.
Yoshida, Izumi, Takeda, Shigeyuki, Homma, Sumiko, Yusufi, Ahad Noor Khan , Douša, Thomas P., Asano, Yasushi, Kusano, Eiji

Mayo Clinic

The Tohoku Journal of Experimental Medicine | February 2, 2005 | Volume: 193 | Issue: 3 | Pages: 207-220

10.1620/tjem.193.207 | PMID 11315768 Get It

2004 Where Do We Go from Here?—Summary of Working Group Discussions on Thyroid Function and Gestational Outcomes
Hollowell, Joseph G., LaFranchi, Stephen, Smallridge, Robert C., Spong, Catherine Y., Haddow, James E. , Boyle, Coleen A.

Mayo Clinic

Thyroid | February 1, 2005 | Volume: 15 | Issue: 1 | Pages: 72-76

10.1089/thy.2005.15.72 | PMID 15687826 Get It

Thyroid Function Inside and Outside of Pregnancy: What Do We Know and What Don't We Know?
Smallridge, Robert C., Glinoer, Daniel, Hollowell, Joseph G., Brent, Gregory A.

Mayo Clinic

Thyroid | February 1, 2005 | Volume: 15 | Issue: 1 | Pages: 54-59

10.1089/thy.2005.15.54 | PMID 15687824 Get It

Subclinical Thyroid Dysfunction: A Joint Statement on Management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society
Gharib, Hossein, Tuttle, R. Michael , Baskin, H. Jack, Fish, Lisa H. , Singer, Peter, McDermott, Michael T.

Mayo Clinic

Thyroid | February 1, 2005 | Volume: 15 | Issue: 1 | Pages: 24-28

10.1089/thy.2005.15.24 | PMID 15687817 Get It

National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention Guidelines
Mosca, Lori, Linfante, Allison H., Benjamin, Emelia J. , Berra, Kathy, Hayes, Sharonne N. , Walsh, Brian W., Fabunmi, Rosalind P., Kwan, Johnny S. H., Mills, Thomas C. , Simpson, Susan Lee, Benjamin, Emelia J , Hayes, Sharonne N

Mayo Clinic

Circulation | February 1, 2005 | Volume: 111 | Issue: 4 | Pages: 499-510

10.1161/01.cir.0000154568.43333.82 | PMID 15687140 Get It

Background— Few data have evaluated physician adherence to cardiovascular disease (CVD) prevention guidelines according to physician specialty or patient characteristics, particularly gender. Methods and Results— An online study of 500 randomly selected physicians (300 primary care physicians, 100 obstetricians/gynecologists, and 100 cardiologists) used a standardized questionnaire to assess awareness of, adoption of, and barriers to national CVD prevention guidelines by specialty. An experimental case study design tested physician accuracy and determinants of CVD risk level assignment and application of guidelines among high-, intermediate-, or low-risk patients. Intermediate-risk women, as assessed by the Framingham risk score, were significantly more likely to be assigned to a lower-risk category by primary care physicians than men with identical risk profiles ( P <0.0001), and trends were similar for obstetricians/gynecologists and cardiologists. Assignment of risk level significantly predicted recommendations for lifestyle and preventive pharmacotherapy. After adjustment for risk assignment, the impact of patient gender on preventive care was not significant except for less aspirin ( P <0.01) and more weight management recommended ( P <0.04) for intermediate-risk women. Physicians did not rate themselves as very effective in their ability to help patients prevent CVD. Fewer than 1 in 5 physicians knew that more women than men die each year from CVD. Conclusions— Perception of risk was the primary factor associated with CVD preventive recommendations. Gender disparities in recommendations for preventive therapy were explained largely by the lower perceived risk despite similar calculated risk for women versus men. Educational interventions for physicians are needed to improve the quality of CVD preventive care and lower morbidity and mortality from CVD for men and women.
Syndromic patent ductus arteriosus: Evidence for haploinsufficient TFAP2B mutations and identification of a linked sleep disorder
Radhakrishnan, Jayaram, Farhi, Anita, Carew, Khary S., Warnes, Carole A. , Nelson‐Williams, Carol , Day, Ronald W. , Pober, Barbara R. , State, Matthew W. , Lifton, Richard P. , Mani, Arya

Mayo Clinic

Proceedings of the National Academy of Sciences | January 31, 2005 | Volume: 102 | Issue: 8 | Pages: 2975-2979

10.1073/pnas.0409852102 | PMID 15684060 Get It

Patent ductus arteriosus (PDA) is a common congenital heart disease that results when the ductus arteriosus, a muscular artery, fails to remodel and close after birth. A syndromic form of this disorder, Char syndrome, is caused by mutation in TFAP2B , the gene encoding a neural crest-derived transcription factor. Established features of the syndrome are PDA, facial dysmorphology, and fifth-finger clinodactyly. Disease-causing mutations are missense and are proposed to be dominant negative. Because only a small number of families have been reported, there is limited information on the spectrum of mutations and resulting phenotypes. We report the characterization of two kindreds (K144 and K145) with Char syndrome containing 22 and 5 affected members, respectively. Genotyping revealed linkage to TFAP2B in both families. Sequencing of TFAP2B demonstrated mutations in both kindreds that were not found among control chromosomes. Both mutations altered highly conserved bases in introns required for normal splicing as demonstrated by biochemical studies in mammalian cells. The abnormal splicing results in mRNAs containing frameshift mutations that are expected to be degraded by nonsense-mediated mRNA decay, resulting in haploinsufficiency; even if produced, the protein in K144 would lack DNA binding and dimerization motifs and would likely result in haploinsufficiency. Examination of these two kindreds for phenotypes that segregate with TFAP2B mutations identified several phenotypes not previously linked to Char syndrome. These include parasomnia and dental and occipital-bone abnormalities. The striking sleep disorder in these kindreds implicates TFAP2B-dependent functions in the normal regulation of sleep.